ShareValue scores for 688712.SHG: Valuation 22, Quality 79, Growth 57, Health 65.
688712.SHGSSE
Insight Lifetech Co., Ltd.
CN¥29.00
(-1.06%)
Updated
688712.SHGSSE
Insight Lifetech Co., Ltd.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Shanghai-listed Healthcare stocks
Company Details
Insight Lifetech Co., Ltd. engages in research, development, production, and sales of interventional medical devices in the field of precision diagnosis and treatment of cardiovascular diseases in China and internationally. The company provides Coronary intervention products, including precision and complex percutaneous coronary intervention products, such as intracavitary imaging and physiological function products; peripheral vascular interventional diagnostic and treatment products; and electrophysiological products. It offers TruePhysio rapid exchange pressure microcatheter, VivoHeart intravascular ultrasound console, VivoCardio cardiovascular pressure measurement system, TRUEVISION HD imaging catheter, TrueCross microcatheter, TrueReach dual-lumen microcatheter, and TrueExtensio guide extension catheter. The company also provides clinical support and academic promotion related to its products, and engages in research and development, manufacturing, and commercialization of medical technologies. Insight Lifetech Co., Ltd. was incorporated in 2015 and is headquartered in Shenzhen, China.
Score Analysis
AI Investment Thesis
Insight Lifetech Co., Ltd. is overvalued: its P/E of 86.2 is higher than 79% of Shanghai-listed Healthcare stocks, P/B of 6.13 higher than 85%, and P/S of 16.0 higher than 88%.
Quality is the strongest pillar, with an 18.2% net margin versus a negative global sector average, though ROE of 9.76% still trails the multiple implied by a 6.1x book valuation.
Third-quarter results published 27 October 2026 showed revenue up 32.7% to CN¥196.3 million and nine-month net income up 70% to CN¥133 million.